Osimertinib therapy exhibits acceptable efficacy in patients with T790M mutation-positive advanced NSCLC with EGFR-TKI resistance and poor PS; however, adverse events and ILD should be considered. Here, EGFR is linked to non-small cell lung carcinoma.